Answers are grounded in this paper and cite their sources.
BACKGROUND: Tertiary lymphoid structures (TLSs) support local adaptive immunity and are associated with favorable antitumor responses across multiple cancers. However, how anticancer treatment reshapes TLS maturation, particularly in lung cancer brain metastasis (LCBM), remains poorly understood. METHODS: We integrated clinicopathological profiling of LCBM cohorts with bulk and single-cell RNA sequencing, spatial profiling, immune-repertoire analysis, histological validation, and murine intracranial tumor models. Associations between prior treatment and TLS maturation were evaluated using multivariable analyses. Mechanistic studies examined chemotherapy-associated IL-33 release, mast-cell activation, and the effects of PGD2 on antigen-specific T-cell cytotoxicity and B-cell differentiation. Pharmacological inhibition of H-PGDS and mast-cell stabilization were further evaluated in vivo. RESULTS: Mature TLSs were associated with favorable survival in patients with LCBM, whereas preoperative chemotherapy was independently associated with impaired TLS maturation after adjustment for measured clinical and treatment covariates. Consistent with this observation, chemotherapy-treated tumors exhibited increased IL-33 levels, mast-cell accumulation, and enhanced mast-cell degranulation, with spatial analyses placing activated mast cells within TLS-associated immune niches. Mechanistically, IL-33 activated ST2-expressing mast cells, induced NF-κB-associated transcriptional programs. Functionally, mast cell-derived PGD2 suppressed antigen-specific CD8⁺ T-cell cytotoxicity and impaired plasma-cell differentiation, providing a potential link between chemotherapy and weakened local adaptive immunity. In vivo, pharmacological inhibition of H-PGDS enhanced chemotherapy efficacy, while mast-cell stabilization with cromolyn sodium reduced chemotherapy-associated degranulation, increased local adaptive immune-cell infiltration, improved intracranial tumor control, and prolonged survival when combined with chemotherapy. CONCLUSIONS: Our findings support a model in which chemotherapy-associated tissue stress activates an IL-33-responsive mast-cell program and restrains TLS-associated adaptive immunity in LCBM. Although this pathway is unlikely to operate as an exclusively linear or mast-cell-specific mechanism, targeting mast-cell-associated inflammatory signaling may provide a strategy to preserve antitumor immunity and improve the therapeutic efficacy of chemotherapy in brain metastasis.
No takes yet. Share an insight, caveat, or question.
Fu et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: